What it is

Long-acting amylin analog studied alone and with GLP-class ligands.

Also known as

CAGRI · Long-acting amylin analog

Overview

Cagrilintide is a long-acting amylin receptor agonist analog studied for satiety and metabolic-signaling research. Amylin pathways complement incretin biology, so the compound appears both as a standalone tool and in combination designs with GLP-class ligands.

Laboratory work focuses on food-intake, gastric-emptying-related, and body-composition endpoints in metabolic models. Left Turn Adventures supplies this compound for laboratory and research use only.

Proven benefits

Note: Preclinical / literature endpoints for labs — not established human treatment benefits. Not a protocol.

• Amylin-receptor satiety signaling endpoints

• • Food-intake and energy-balance readouts in metabolic models

• • Combination-study markers with GLP-class agonists

• • Body-composition endpoints in longer preclinical windows

• • Gastric-emptying–adjacent physiologic measures where reported

Results timeline

Note: Illustrative research-observation windows — not a clinical schedule. No dosing.

• Week 1–2: Early receptor-engagement and appetite/energy-signaling readouts in model systems; compound exposure establishing.

• • Week 3–4: Clearer metabolic and satiety-pathway markers in short preclinical windows.

• • Month 2–3: More stable body-composition and glucose/lipid-related endpoints where studied.

• • Month 3–6: Sustained metabolic-signaling observations in longer research designs.

Footer RUO

The catalog, not a clinic

For laboratory and research use only. Not for human or animal consumption. Products are sold solely to qualified researchers and licensed laboratories. No dosing or reconstitution on this page.